AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $562.03 million. The enterprise value is $168.60 million.
| Market Cap | 562.03M |
| Enterprise Value | 168.60M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 26.76 million shares outstanding. The number of shares has decreased by -4.41% in one year.
| Shares Outstanding | 26.76M |
| Shares Change (YoY) | -4.41% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 113.52% |
| Float | 14.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.57 |
| Forward PS | 33.20 |
| PB Ratio | 6.15 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.87, with a Debt / Equity ratio of 0.20.
| Current Ratio | 10.87 |
| Quick Ratio | 10.62 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -119.40% and return on invested capital (ROIC) is -155.23%.
| Return on Equity (ROE) | -119.40% |
| Return on Assets (ROA) | -32.60% |
| Return on Capital (ROIC) | -155.23% |
| Revenue Per Employee | $146,641 |
| Profits Per Employee | -$1.40M |
| Employee Count | 117 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.23% in the last 52 weeks. The beta is -0.29, so AnaptysBio's price volatility has been lower than the market average.
| Beta (1Y) | -0.29 |
| 52-Week Price Change | -12.23% |
| 50-Day Moving Average | 22.96 |
| 200-Day Moving Average | 20.06 |
| Relative Strength Index (RSI) | 36.17 |
| Average Volume (30 Days) | 327,327 |
Short Selling Information
The latest short interest is 4.27 million, so 15.95% of the outstanding shares have been sold short.
| Short Interest | 4.27M |
| Short Previous Month | 4.30M |
| Short % of Shares Out | 15.95% |
| Short % of Float | 28.98% |
| Short Ratio (days to cover) | 9.52 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $17.16 million and -$163.62 million in losses. Loss per share was -$6.08.
| Revenue | 17.16M |
| Gross Profit | 17.16M |
| Operating Income | -164.41M |
| Pretax Income | -163.62M |
| Net Income | -163.62M |
| EBITDA | -161.25M |
| EBIT | -163.62M |
| Loss Per Share | -$6.08 |
Balance Sheet
The company has $390.90 million in cash and $17.81 million in debt, giving a net cash position of $373.09 million or $13.94 per share.
| Cash & Cash Equivalents | 390.90M |
| Total Debt | 17.81M |
| Net Cash | 373.09M |
| Net Cash Per Share | $13.94 |
| Equity / Book Value | 88.10M |
| Book Value Per Share | 3.29 |
| Working Capital | 369.39M |
Cash Flow
In the last 12 months, operating cash flow was -$120.80 million and capital expenditures -$807,000, giving a free cash flow of -$121.61 million.
| Operating Cash Flow | -120.80M |
| Capital Expenditures | -807,000 |
| Free Cash Flow | -121.61M |
| FCF Per Share | -$4.52 |
Margins
Gross margin is 100.00%, with operating and profit margins of -958.27% and -953.66%.
| Gross Margin | 100.00% |
| Operating Margin | -958.27% |
| Pretax Margin | -953.68% |
| Profit Margin | -953.66% |
| EBITDA Margin | -939.83% |
| EBIT Margin | -953.68% |
| FCF Margin | -708.79% |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.41% |
| Shareholder Yield | 4.41% |
| Earnings Yield | -30.21% |
| FCF Yield | -22.45% |
Analyst Forecast
The average price target for AnaptysBio is $46.22, which is 120.10% higher than the current price. The consensus rating is "Buy".
| Price Target | $46.22 |
| Price Target Difference | 120.10% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 31.61% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of -1.18 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.18 |
| Piotroski F-Score | 4 |